Grifols (NASDAQ:GRFS) has entered into an agreement to acquire the remaining equity of Alkahest in exchange for a total price of $146M, on a debt-free basis. No additional financing will be required.

The transaction is expected to close in early 2021.

Alkahest is a clinical stage biopharmaceutical company dedicated to discovering and developing treatments for neurodegenerative and age-related diseases with therapies targeting the aging plasma proteome.

See GRFS total return performance vs. S&P 500 and other convalescent plasma players over past six months.


Source link